. Author manuscript; available in PMC: 2018 Dec 1.

Published in final edited form as: Lancet Infect Dis. 2017 Sep 22;17(12):1255–1265. doi: 10.1016/S1473-3099(17)30476-0

Table 3.

Clinical Efficacy by treatment arm (median estimate, 95% CI)

		Combination Antivirals (N=230)	Oseltamivir (N=224)	p value
Efficacy Population	Duration of clinical symptoms (days)	4·5 (4·0–5·0)	4·0 (3·5–4·5)	0·21
	Duration of fever ^# (days)	1·0 (1·0,1·5)	1·0 (0·5,1·5)	0·59
	Duration of clinical symptoms and /or fever (days)	5·0 (4·5–6·0)	4·0 (3·5–5·0)	0·10
	Duration of time to feel as good as before the onset of the influenza illness (days)	7·5 (7·0–8·0)	6·5 (6·0–7·5)	0·009
	Duration of time to return to pre-influenza function (days)	7·0 (6·0–7·5)	6·0 (5·0–6·5)	0·019
		Combination Antivirals (N=314)	Oseltamivir (N=312)	p value
ITT Population	Duration of clinical symptoms (days)	4·5 (4·0–5·0)	4·0 (3·5–4·5)	0·44
	Duration of fever ^# (days)	1·0 (^*)	1·0 (0·5,1·0)	0·69
	Duration of clinical symptoms and fever (days)	4·5 (4·0–5·0)	4·5 (4·0–5·0)	0·30
	Duration of time to feel as good as before the onset of the influenza illness (days)	7·5 (7·0–7·5)	6·5 (6·0–7·0)	0·003
	Duration of time to return to pre-influenza function(days)	7·0 (6·0–7·5)	6·0 (5·0–6·5)	0·009

restricted to those with fever at randomization

confidence interval not estimable